Search results for "HB"

showing 10 items of 1066 documents

Development of a simple, biocompatible and cost-effective Inulin-Diethylenetriamine based siRNA delivery system

2015

Small interfering RNAs (siRNAs) have the potential to be of therapeutic value for many human diseases. So far, however, a serious obstacle to their therapeutic use is represented by the absence of appropriate delivery systems able to protect them from degradation and to allow an efficient cellular uptake. In this work we developed a siRNA delivery system based on inulin (Inu), an abundant and natural polysaccharide. Inu was functionalized via the conjugation with diethylenetriamine (DETA) residues to form the complex Inu-DETA. We studied the size, surface charge and the shape of the Inu-DETA/siRNA complexes; additionally, the cytotoxicity, the silencing efficacy and the cell uptake-mechanis…

3003Small interfering RNAJHH6CellPharmaceutical ScienceEndocytosisCell LineIn vivoCell Line TumormedicinePolyaminesGene silencingHumansMicropinocytosisRNA Small InterferingCytotoxicityChemistry16HBEInulinEndocytosisDiethylenetriamine (DETA)Cell biologyInu-DETA copolymermedicine.anatomical_structureBiochemistryCytoplasmSettore CHIM/09 - Farmaceutico Tecnologico ApplicativosiRNA16HBE; Diethylenetriamine (DETA); Inu-DETA copolymer; Inulin; JHH6; siRNA; 3003E2F1 Transcription Factor
researchProduct

Bim and architectural heritage: Towards an operational methodology for the knowledge and the management of cultural heritage

2016

The study aims to answer the growing need for virtuously organize informational apparatuses related to Cultural Heritage. We propose a methodology that integrates multidisciplinary processes of interaction with information aimed at survey, documentation, management, knowledge and enhancement of historic artifacts. It is needed to review and update the procedure of instrumental data acquisition, standardization and structuring of the acquired data in a three-dimensional semantic model as well as the subsequent representability and accessibility of the model and the related database. If the use of Building Information Modeling has in recent years seen a consolidation in the procedures and the…

3d modeling Big data Cultural heritage HbimVirtual heritageArchitectureArchitectural drawing and designSettore ICAR/17 - Disegnocultural heritage virtual heritage big data hbim 3d modelingNA1-9428NA2695-2793
researchProduct

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

Scattering Studies with Low-Energy Kaon-Proton Femtoscopy in Proton-Proton Collisions at the LHC

2020

The study of the strength and behaviour of the antikaon-nucleon ($\mathrm{\overline{K}N}$) interaction constitutes one of the key focuses of the strangeness sector in low-energy Quantum Chromodynamics (QCD). In this letter a unique high-precision measurement of the strong interaction between kaons and protons, close and above the kinematic threshold, is presented. The femtoscopic measurements of the correlation function at low pair-frame relative momentum of (K$^+$ p $\oplus$ K$^-$ $\overline{\mathrm{p}}$) and (K$^-$ p $\oplus$ K$^+$ $\overline{\mathrm{p}}$) pairs measured in pp collisions at $\sqrt{s}$ = 5, 7 and 13 TeV are reported. A structure observed around a relative momentum of 58 Me…

:Kjerne- og elementærpartikkelfysikk: 431 [VDP]Protonchiral dynamicsGeneral Physics and Astronomyhiukkasfysiikkanucl-ex01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ALICELHC HBTCorrelation functionHBT[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]scattering [p p]correlation functionKaon-ProtonNuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentQuantum chromodynamicsPhysicsLarge Hadron ColliderPhysicsstrong interactionCHIRAL DYNAMICSVDP::Kjerne- og elementærpartikkelfysikk: 431SIGMA-HYPERON PRODUCTIONddc:3. Good healthPRIRODNE ZNANOSTI. Fizika.p interactions:Nuclear and elementary particle physics: 431 [VDP]CERN LHC CollNUCLEON INTERACTIONSVDP::Nuclear and elementary particle physics: 431P INTERACTIONSIsospinLHC5000 GeV-cms/nucleon 7000 GeV-cms/nucleon 13000 GeV-cms/nucleonpp collisionsParticle Physics - Experimentp p: scatteringStrong interactionLAMBDA(1405)Kaon-Proton Femtoscopy pp collisions LHCFOS: Physical sciences[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]Physics and Astronomy(all)Strangenesslambda(1405)114 Physical sciencesALICE; femtoscopyp-pNuclear physicsMomentumALICE LHC High-Energy Physicschiral [model]strangenessnucleon interactionsKaon-Proton ; Femtoscopy ; p-pfemtoscopyquantum chromodynamics0103 physical sciencesNuclear Physics - Experimentddc:530010306 general physicsNuclear Physicsanti-K nucleon: interactionhep-exHigh Energy Physics::PhenomenologySIGMA-HYPERON PRODUCTION; NUCLEON INTERACTIONS; CHIRAL DYNAMICS; P INTERACTIONS; LAMBDA(1405)interaction [anti-K nucleon]mass differenceNATURAL SCIENCES. Physics.Kaon-Proton Femtoscopysigma-hyperon productionHigh Energy Physics::Experimentmodel: chiralexperimental results
researchProduct

Polyoxypregnanes as safe, potent, and specific ABCB1-inhibitory pro-drugs to overcome multidrug resistance in cancer chemotherapy in vitro and in vivo

2021

Multidrug resistance (MDR) mediated by ATP binding cassette subfamily B member 1 (ABCB1) is significantly hindering effective cancer chemotherapy. However, currently, no ABCB1-inhibitory drugs have been approved to treat MDR cancer clinically, mainly due to the inhibitor specificity, toxicity, and drug interactions. Here, we reported that three polyoxypregnanes (POPs) as the most abundant constituents of Marsdenia tenacissima (M. tenacissima) were novel ABCB1-modulatory pro-drugs, which underwent intestinal microbiota-mediated biotransformation in vivo to generate active metabolites. The metabolites at non-toxic concentrations restored chemosensitivity in ABCB1-overexpressing cancer cells v…

ABCC1 ATP binding cassette subfamily C member 1IC50 half maximal inhibitory concentrationMultidrug resistancePharmacologyNADPH reduced nicotinamide adenine dinucleotide phosphateF bioavailabilitychemistry.chemical_compoundPCR polymerase chain reaction0302 clinical medicineMDR multidrug resistanceECL electrochemiluminescencet1/2 elimination half-lifeLC–MS liquid chromatography coupled with mass spectrometryN.D. not detectedGeneral Pharmacology Toxicology and PharmaceuticsBBB blood–brain barriermedia_commonATF3 activating transcription factor 30303 health sciencesChemistryABC ATP-binding cassetteNMPA National Medical Products AdministrationPXR pregnane X receptorSDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresisHBSS Hankʹs balanced salt solutionABCB1Combination chemotherapyProdrugMarsdenia tenacissimaCmax peak concentrationPaclitaxelGAPDH glyceraldehyde-3-phosphate dehydrogenase030220 oncology & carcinogenesisBHI brain heart infusionOriginal ArticleAUC0–∞ area under plasma concentration vs. time curveMRT mean residence timeDrugmedia_common.quotation_subjectRM1-950Vd volume of distributionABCB1 ATP binding cassette subfamily B member 1UIC-2 mouse monoclonal ABCB1 antibodyABCG2 ATP binding cassette subfamily G member 2Combination chemotherapyCYP cytochrome P450 isozymePI propidium iodideTEER transepithelial electrical resistance03 medical and health sciencesPBS phosphate buffer salineFBS fetal bovine serumDox doxorubicinIn vivoPOP polyoxypregnanemedicine030304 developmental biologyEVOM epithelial tissue voltohmmeterTmax time for peak concentrationCancerLBE lowest binding energyPE phycoerythrinmedicine.diseaseMultiple drug resistancePolyoxypregnanePapp apparent permeabilityN.A. not applicableCancer cellH&E hematoxylin and eosinMDR1a multidrug resistance protein 1aTherapeutics. PharmacologyqPCR quantitative PCRM. tenacissima Marsdenia tenacissimaCL clearanceSD standard derivationActa Pharmaceutica Sinica B
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Eiropas Savienības un Azerbaidžānas attiecības Eiropas kaimiņattiecību politikas kontekstā

2019

Šajā pētījumā tiek izvērtētas Azerbaidžānas un Eiropas Savienības (ES) divpusējās attiecības. Pētījuma autore analizējusi šo attiecību daudzpusību, kas izpaužas tādās sfērās kā ekonomika, enerģētika, tirdzniecība un politika. Šis pētījums arī uzsver virkni ES pieņemtu politiku, kas saistītas ar Azerbaidžānu, tostarp Eiropas kaimiņattiecību politiku un Austrumu Partnerības programmu. Autore izmantojusi arī empīrisko analīzi, lai izvērtētu cik ciešas ir Azerbaidžānas un ES ekonomiskās un tirdzniecības saites. Ar teorētisku un analītisku pētījumu vērtēta Eiropas Kaimiņattiecību politikas rīcības plāna īstenošana Azerbaidžānā. Autore salīdzinājusi galvenos ekonomiskos statistikas datus starp Ei…

Action PlanEkonomikabilateral relationsEuropean UnionEuropean Neighborhood Policyenergy
researchProduct

Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes: a clinicopathological and m…

2014

ObjectiveAlthough the succinate dehydrogenase (SDH)-related tumor spectrum has been recently expanded, there are only rare reports of non-pheochromocytoma/paraganglioma tumors in SDHx-mutated patients. Therefore, questions still remain unresolved concerning the aforementioned tumors with regard to their pathogenesis, clinicopathological phenotype, and even causal relatedness to SDHx mutations. Absence of SDHB expression in tumors derived from tissues susceptible to SDH deficiency is not fully elucidated.Design and methodsThree unrelated SDHD patients, two with pituitary adenoma (PA) and one with papillary thyroid carcinoma (PTC), and three SDHB patients affected by renal cell carcinomas (RC…

AdenomaAdultMalemedicine.medical_specialtyPathologySDHBEndocrinology Diabetes and MetabolismSDHALoss of HeterozygosityBiologyPheochromocytomaLoss of heterozygosityEndocrinologyParagangliomaInternal medicinemedicineHumansPituitary NeoplasmsThyroid NeoplasmsCarcinoma Renal CellGerm-Line MutationCarcinomaGeneral MedicineExonsMiddle Agedmedicine.diseaseNeuroblastic TumorCarcinoma Papillary3. Good healthNeoplasm ProteinsSuccinate DehydrogenaseEndocrinologyThyroid Cancer PapillaryMutationFemaleSDHDClear cellGene DeletionEuropean Journal of Endocrinology
researchProduct

Glycated serum proteins and glucose tolerance

1988

Glycated serum proteins (GSP), stable glycated hemoglobin (HbA1c) together with some metabolic parameters were evaluated in 120 subjects, 30 with normal glucose tolerance (NGT), 30 with impaired glucose tolerance (IGT), 30 with non-insulin-dependent diabetes mellitus (NIDD), and 30 with insulin-dependent diabetes mellitus (IDD). GSP levels were significantly higher in IGT, NIDD and IDD than in NGT. HbA1c levels were not significantly higher in IGT in comparison with NGT, but were significantly higher in NIDD and in IDD than in NGT and IGT. GSP correlated better than HbA1c with all metabolic parameters considered. Taking into account the distribution of the values, GSP showed a smaller overl…

AdultBlood GlucoseMalemedicine.medical_specialtyGlycosylationendocrine system diseasesEndocrinology Diabetes and MetabolismImpaired glucose toleranceHba1c levelchemistry.chemical_compoundEndocrinologystomatognathic systemReference ValuesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansTriglyceridesGlycated HemoglobinGlucose tolerance testmedicine.diagnostic_testbusiness.industryCholesterolnutritional and metabolic diseasesBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseBlood proteinsCholesterolDiabetes Mellitus Type 1EndocrinologyDiabetes Mellitus Type 2chemistryHyperglycemiaMetabolic control analysisFemaleGlycated hemoglobinbusinesshormones hormone substitutes and hormone antagonistsActa Diabetologica Latina
researchProduct

Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue …

2013

The effect of pegylated interferon-α (IFN) add-on therapy on HBV-specific T-cell responses was evaluated in 12 patients with stable, undetectable hepatitis B virus (HBV) load under nucleos(t)ide analogue therapy. Peripheral blood mononuclear cells were isolated at week 0, 4, 8, 12, 24 and 48 of IFN add-on therapy. Quantity and quality of circulating HBV S- and core-specific CD4 and CD8 T cells were analysed ex vivo by flow cytometry. HBV S- and core-specific CD4 T-cell numbers modestly increased within 8 weeks of IFN administration (P = 0.0391 and P = 0.0195), whereas HBV-specific CD8 T cells in general showed only minor changes under IFN add-on therapy. Functionality of HBV-specific CD4 bu…

AdultCD4-Positive T-LymphocytesMaleHBsAgHepatitis B virusT cellPopulationCD8-Positive T-Lymphocytesmedicine.disease_causeAntiviral AgentsCohort StudiesHepatitis B ChronicAntigenPegylated interferonVirologymedicineCytotoxic T cellHumanseducationTransaminasesHepatitis B viruseducation.field_of_studyHepatitis B Surface AntigensHepatologybusiness.industryInterferon-alphaHepatitis BMiddle Agedmedicine.diseaseFlow CytometryVirologyHepatitis B Core AntigensInfectious Diseasesmedicine.anatomical_structureImmunologyFemalebusinessmedicine.drugJournal of viral hepatitis
researchProduct